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Abstract 
Tumors develop mechanisms to recruit tolerogenic immune cells and to induce the 
expression of molecules that act as immune checkpoints. This regulation of the immune 
microenvironment favors immune tolerance to the neoplastic cells. In this study we have 
investigated the prognostic role of immune-checkpoint expression markers in a cohort of 
resectable NSCLC patients. RNA was isolated from fresh-frozen lung specimens (tumor and 
normal lung) (n=178). RTqPCR was performed to analyze the expression to analyze the 
relative expression of 20 immune-related genes and normalized by the use of endogenous 
genes selected by GeNorm algorithm. Patients with higher expression levels IL23A, and 
LGALS2 presented better outcomes. Clustering expression patterns, we observed that patients 
with higher expression of immunoregulatory genes had better survival rates. Additionally, 
these data was used to develop a gene expression score. Since CTLA-4 and PD-1 were 
associated with prognosis based on COX regression analysis (Z-score> 1.5), a multivariate 
model including these two genes was created. Absolute regression coefficients from this 
analysis were used in order to calculate the immune-checkpoint score: (PD1 x 0.116) + 
(CTLA4 x 0.0589) for each case. Kaplan-Meier survival analysis showed that patients with 
high immune-checkpoint score have longer overall survival (OS) [NR vs 40.4 months, 
p=0.008] and longer relapse-free survival (RFS) [82.6 vs 23 months, p=0.009]. Multivariate 
analysis in the entire cohort indicated that the immune-checkpoint score was an independent 
biomarker of prognosis for OS [HR: 0.308; 95%CI, 0.156-0.609; p=0.001] and RFS [HR: 
0.527; 95%CI, 0.298-0.933; p=0.028] in early-stage NSCLC patients. In conclusion, this 
score provides relevant prognostic information for a better characterization of early-stage 
NSCLS patients with strikingly different outcomes and who may be candidates for immune-




Lung cancer is the most common cause of tumor-related death in the world. 
Approximately 85% are classified as non–small cell lung cancer (NSCLC) and at the time of 
diagnosis the majority of patients present locally advanced or metastatic disease1. 
Improvements in the understanding of the mechanisms for lung cancer initiation, 
maintenance, and progression have led to the discovery of a variety of molecularly defined 
subsets of patients characterized by specific sets of driver mutations2. Lung cancers are 
among the most mutated types of tumors3, therefore generating new antigens which play a 
key part in tumor immunity 4 and improved responses to immune-based therapies in NSCLC 
and other lung tumors5–7. 
Tumor-infiltrating immune cells have been identified in many types of cancers8 and although 
some of these cells are potentially capable of eliminating neoplastic cells, ultimately they 
cannot prevent tumor development and progression9. In NSCLC it has been shown that the 
presence, localization and proportion of helper and specially cytotoxic infiltrating 
lymphocytes are associated with a favorable prognosis10–13. But tumors acquire mechanisms 
to regulate their immune microenvironment such as the release of a series of factors to subvert 
normal reaction mechanisms as the modulation of co-stimulatory pathways, also known as 
immune checkpoints14, and the induction and attraction of suppressor cells such as myeloid-
derived suppressor cells15,16, tumor-associated macrophages17, and regulatory T cells18,19. The 
clinical implications of these immunoregulatory elements in tumors are still controversial20, 
and their functional or causal relationship between immunosuppressive pathways and immune 
cells in the tumor microenvironment has not yet been clearly defined in NSCLC21–24. 
Therefore, the study of a great variety of immune-related markers, especially those implicated 
in immunoregulatory processes, could provide valuable prognostic information that could 
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help in many applications in future NSCLC clinical practice. Additionally, and regarding 
laboratory assessments to determine these markers, it is of crucial importance to develop 
robust methodologies that are not biased by observer subjectivity, are reproducible and allow 
accurate and affordable large scale determinations. In this study with a cohort of surgically-
resected NSCLC patients we have investigated the prognostic value of the quantification of 
gene expression levels of a large array of immunoregulatory molecules (mRNA by RTqPCR). 
In this article, we demonstrate for the first time the prognostic relevance of an immune 
checkpoint score based on the relative expression of two immune checkpoint molecules in 





The most relevant demographic and clinicopathological characteristics including age, gender, 
stage of disease and histology of the 178 NSCLC patients entered in the study are shown in 
Table 1. The median patient age was 65 years [range: 26-85], 86.5% were male, 47.2% had 
SCCs, and 59% of the patients were diagnosed at stage I of the disease. Moreover, 80 (45%) 
relapsed and 76 (42.7%) died during the follow-up. The median follow-up was of 81.23 
months [Range: 1-113]. 
Immune-related gene expression patterns and their association with survival 
We measured the expression of 20 immune-related genes in primary lung tumor and paired 
noncancerous tissues (adjacent healthy lung tissue) using RTqPCR. Using this criteria, we 
found that FOXP3 (3.87X) and CD25 (2.66X) were overexpressed, whilst CD1C (0.42X), 
CD127 (0.40X), PD1 (0.38X), and CCL2 (0.25X) were downregulated in the tumor compared 
to normal-paired tissue. Unsupervised hierarchical clustering analysis was used to group 
patients based on the similarity of their expression patterns. Patients were classified into a 
cluster tree with two major subgroups according to the expression of genes related to 
conventional and regulatory T cells (CD4, CD8, CD127, FOXP3, CD25, CTLA4, PD1 and 
PDL1) and genes involved in different immunoregulatory processes (IL10, IL23A, CCL2, 
NRP1, LGALS1, LGALS2, CD1C, and CD209). Patients in Cluster I had lower expression 
levels of most of the genes analyzed, whilst Cluster II comprised patients with higher gene 
expression levels (Figure 1).  
Kaplan-Meier survival analysis using the two major clusters showed that patients in Cluster II 
had longer relapse free survival (RFS) (81.2 vs. 26.2 months, p = 0.027) and overall survival 
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(OS) (not reached (NR) vs. 46.6 months, p = 0.040) than patients in Cluster I (Figure 2). We 
also analyzed their prognostic value according to histology, and observed that ADC patients 
classified in Cluster II had a significantly better RFS (81.2 vs. 17.8 months, p = 0.005) and 
OS (NR vs. 42.9 months, p = 0.034) than patients in Cluster I. Although it is of interest that 
the unsupervised cluster analysis of immune-related genes was able to identify a group of 
patients with a better prognosis, hierarchical clustering can only be applied retrospectively 
and cannot be used to predict a patient’s future outcome. Therefore, next we investigated the 
prognostic value of genes analyzed individually or as small groups. 
Individual immune-related genes associated with survival 
Kaplan-Meier analysis was carried out indicated that patients with high levels of IL23A 
presented better RFS (81.2 vs. 23.4 months, p = 0.003; Supplementary Figure 1a-b) and better 
OS (NR vs. 43.4 months, p = 0.001). Another gene that correlated with better RFS (NR vs. 
26.2 months, p=0.002) and OS (NR vs. 46.6, p=0.007) was LGALS2, which encodes galectin-
2 (Supplementary Figure 1c-d).  
Survival analysis was also performed according to the patient histology. Kaplan-Meier test 
performed with ADC patients (including ADCs and adenosquamous histology), showed the 
same association between high IL23A and LGALS2 and better prognosis that were found in 
the entire cohort. Furthermore, the group of patients with high CTLA4 expression levels had 
better RFS (81.2 vs. 18.2 months, p = 0.002, Supplementary Figure 2a-b) and OS (NR vs. 37 
months). We also found that high levels of IL10 correlated with a higher RFS (49.3 vs. 18.8 
months, p = 0.029, Supplementary Figure 2c-d) and OS (81.2 vs. 37 months, p = 0.030). 
Immune checkpoint score (ICS) is a prognostic biomarker for RFS and OS in NSCLC 
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We also intended to create a gene expression score based on a multi-gene signature, which 
can provide more accurate predictions than a model using single genes25,26. Univariate Cox 
regression analysis was performed considering overall survival as a dependent variable. 
Genes were ordered on the basis of their prognostic power (univariate Z-score, 
Supplementary Figure 3) and according to this ranking, the expression of two genes, PD1 and 
CTLA4 (both considered immune checkpoint molecules), were found to be associated with 
survival (Z-score >2), and therefore, were selected to construct a risk signature. We 
constructed a model based on the relative contribution of these two genes in the multivariate 
analysis (considering the absolute regression coefficients, see table 2), and the resulting score 
was named ICS (Immune Checkpoint Score), with the following equation: (PD1 x 0.116) + 
(CTLA4 x 0.058).  
Kaplan-Meier analysis showed that patients with a high ICS (> median) had longer RFS (82.6 
vs. 23 months, p = 0.009; Figure 3) and OS (NR vs. 40.4 months, p = 0.008). We also 
performed a stratified analysis by TNM staging and histology. We found that for ADC 
patients, the association between high ICS and prognosis was stronger than for the entire 
cohort of patients (RFS: NR vs. 16.2 months, p < 0.001 and OS: NR vs. 34.4 months, p = 
0.002). To evaluate the potential use of the ICS as an independent prognostic biomarker, a 
multivariate analysis was performed, where significant analytical and clinicopathological 
variables from the univariate analysis were entered in the study. The variables included were: 
Lymph node involvement, KRAS status, cluster classification, FOXP3, CD4, CD127, IL23, 
LGALS2, the expression score, and the immune checkpoint score. Results obtained from this 
multivariate analysis indicated that KRAS status and the immune checkpoint score were 
independent biomarkers for both OS and RFS, and in the later, CD127 expression was also 




Although most of the patients in early stage NSCLC (stages I-IIIA) are treated 
surgically with curative intent, the associated survival is less than optimal, with a 5-year 
survival rate ranging from 50% for stage IA to 15% for stage IIIA27. Currently, there are still 
gaps in the approach used for selecting patient’s adjuvant therapies based on the surgical or 
TNM stage alone. So, a great challenge in the management of patients with resected NSCLC 
is to develop new biomarkers that could help in identifying subjects at the greatest risk of 
recurrence and their potential response to specific treatments. Over the last decade, the field 
of tumor immunology has changed, and it is now accepted that the immune system plays a 
pivotal role in cancer. We are in the immunotherapy era not only for the efficacy of the new 
therapeutic armamentarium based in the blockage of immune checkpoint inhibitors but also 
for the relevance of the immune-derived prognostic and predictive biomarkers related to 
immunoregulatory processes. Thus, the studies of immune-related markers, especially those 
implicated in immunoregulatory processes, like our paper, could provide valuable prognostic 
information in resected NSCLCs that could help in future clinical practice. 
Infiltrating immune cells of the acquired and innate immune response are organized in the 
lung tissue20,28 and their scoring of the type, density and localization has demonstrated to be a 
prognostic factor in cancer, even as useful as the pathological characteristics9,10. Additionally, 
in the tumor, cancer cells and other components of the microenvironment release chemokines 
and chemokine receptors29,30 that on one side regulate the migration of immune cells31,32 and 
on the other side act as molecules that promote the proliferation and migration of the 
neoplastic cells33,34. A favorable environment for the growth of tumor cells implies the 
specific attraction of cells with known immunosuppressive properties as regulatory T cells, 
Tregs35–37 and myeloid-derived suppressor cells (MDSCs)38–41. Moreover, cancer cells can 
produce cytokines with immunosuppressive functions as IL-1042 and TGF-beta43 together 
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with enzymes such as indoleamine 2,3-dioxygenase (IDO)44 that can impair metabolites 
needed for immune cells to thrive in the environment. But of special interest is the capability 
of the tumoral cells to express certain immune checkpoint receptors that promote tolerance of 
the immune system to the tumoral cells and lead the escape from immune surveillance. The 
maximum exponents of the checkpoint receptor are the cytotoxic T-lymphocyte–associated 
protein-4 (CTLA-4)45, programmed cell death protein-1 (PD-1) and its ligand PD-L146,47. In 
our work we have analyzed the expression levels by RTqPCR of a large variety of cellular 
and soluble immuneregulation-related biomarkers associated with components of the 
physiologic or pathophysiologic immune response. 
In this study gene expression immune-related biomarkers were assessed in fresh-frozen tumor 
and normal lung tissue samples from resected-NSCLC patients. An introductory analysis 
based on unsupervised clustering of the immune-related genes indicated that the group of 
patients with the highest expression levels of immune-related genes had better outcomes than 
the other group, although most of these genes were involved in immunoregulatory processes. 
This is not the first study to observe that patients with higher expression of genes related to 
immunoregulation have better survival rates48. In fact, in breast cancer, a molecular signature 
obtained from microarray data analysis, which was associated with relapse-free patients had a 
higher representation of genes involved in B cell development and antigen presentation, but 
also of genes involved in T-cell apoptosis, CTLA4 signaling, or activation of IL23R, which 
are all pathways involved in the negative regulation of effector T cells49. In a recent study, the 
expression of immunosuppressive factors such as PD1, PDL1, CTLA4, and FOXP3 measured 
in 481 breast tumors, were highly significant predictors of therapy response and improved 
outcome50. Our observations are consistent with the present idea that there are two different 
phenotypes regarding the tumoral infiltration of immune cells, in the sense that the most 
immune components present in the tumoral microenvironment, even if they are 
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immunoregulatory, the better prognosis of the disease51. By contrast those tumors that are not 
able to recruit immune cells had worst prognosis48,52.  
Since hierarchical clustering can only be applied retrospectively and cannot be used to predict 
a patient’s future outcome, we investigated the prognostic value of genes analyzed 
individually. This individual survival analysis revealed associations between markers like 
IL23A, and LGALS2 with better outcomes. IL23 is considered the master switch in several T 
cell-mediated inflammatory disorders, but the antitumor activity of IL23 is controversial. On 
the one hand, it has been shown that pro-inflammatory cytokines, including IL17A, IL6, and 
IL23 can impair CD8+ T cell-mediated immune surveillance and promote tumor 
neovascularization53. But on the other hand, other groups have reported that IL23 exerts 
antitumor activity by stimulating T cells and natural killer (NK) cells54. Its prognostic value 
was studied in ovarian cancer, and an improved OS was observed in patients with high p19 
mRNA expression (expressed by the IL23A gene)55. In lung cancer, a recent study in NSCLC 
tumor samples and cell lines reported that gemcitabine, a chemotherapy drug indicated for 
first-line treatment of NSCLC, induced IL23A expression and that it was found to induce 
NSCLC cell line proliferation. However, they failed to correlate IL23A expression with 
NSCLC patient prognosis56. A for LGALS2, in contrast to galectin-1 and galectin-3, 
relatively few studies have examined the expression of galectin-2 in animals and human 
tumors. Galectins are members of a highly conserved family of β-galactoside-binding lectins, 
which have a broad variety of functions including immune function regulation. The most 
extensively-studied galectin function is their regulation of apoptosis. Furthermore, galectin-1 
functions as a soluble mediator used by tumor cells to evade the immune response57. Similar 
to our findings that lower LGALS2 expression is associated with a worse outcome, in gastric 
cancer, it has been reported that decreased galectin-2 expression is associated with LN 
involvement and advanced clinical stage58. 
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In other to get a deeper insight into the immune regulatory process, a score composed with the 
expression of immune checkpoint related genes (ICS, immune checkpoint score) was 
constructed following a mathematical model25,26. Expression scores are well established 
methods for separating patients into prognostic group and our score includes the expression 
levels and regression coefficients from the cox analysis of CTLA4 and PD1, as follows, ICS = 
(PD1 x 0.116) + (CTLA4 x 0.058). When dichotomizing the cohort attending to the median 
level of the ICS, the Kaplan Meier analysis revealed that a high ICS (ICS above the median) 
was associated with longer OS and RFS. The ICS in the Cox regression model, including all 
the significant variable, demonstrated to be an independent prognostic biomarker, along with 
KRAS status. The ICS encompasses the expression of two genes, CTLA4 and PD1, which 
have become of great interest in the last few years. CTLA4 overexpression is more common 
in ADC and appears to be an independent prognostic factor in NSCLC45. This is because 
researchers have demonstrated the importance of how the immune checkpoint blockade leads 
to robust antitumor effects in patients with metastatic melanoma, NSCLC, and other tumor 
types. In fact, targeted therapy with blocking antibodies to this immune checkpoint are one of 
the more promising therapeutics in many different tumors. So regarding the prognostic 
implication of CTLA-4 expression in NSCLC there are contradictory and opposite results in 
the literature. It has been described that high expression of CTLA-4, but not PDCD1 predicts 
worse survival in NSCLC46 and other malignancies like nasopharyngeal59 or esophageal 
carcinoma60. Contrarily, other authors have found a reduced death rate in radically resected 
NSCLC overexpressing CTLA-445. 
In our cohort, we have found that for ADC patients, the association between high ICS and 
prognosis was stronger than for the entire group of patients. This results are in concordance 
with recent reports that indicate that in squamous NSCLC treated with nivolumab, an anti-
PD1 monoclonal antibody, the improvement in overall survival was independent of PD-L1 
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expression61 while in contrast for nonsquamous NSCLC this benefit was only observed in 
those patients with PD-L1 expression62. In a similar way, PD1 is also an immune checkpoint 
receptor with immunosuppressive properties. However, in contrast to CTLA4, PD1 is 
activated during the effector stages of T cell activation, interaction with its ligand (PDL1) 
occurs primarily in peripheral tissues instead of lymph nodes, and importantly, it can be 
expressed in tumor tissue as well as in immune cells47,63. The expression of immune 
checkpoints, PD1 and PDL1, in infiltrating immune cells by IHC was correlated with better 
responses to immune checkpoint blockade treatment, suggesting that the presence of these 
biomarkers might indicate that these tumors have already been recognized by the immune 
system, and therefore they are key predictors of clinical treatment responses52,64. Additionally, 
in one publication the expression of PD1 and PDL1 in a cohort of 125 NSCLC has been 
assessed in tissues in order to evaluate if they were differently expressed according to the 
presence or absence of EGFR mutations, ALK translocation, or KRAS mutations. Although 
they observed that the sensitivity to treatment was higher and the OS was longer in patients 
treated with EGFT TKIs when PDL1 expression was higher, no differences were observed for 
PD147. As for PDL1, its expression in two large NSCLC patient cohorts has been analyzed, 
observing that high expression of PDL1 protein or mRNA was associated with a better 
outcome24. Furthermore, tumor PD-L1 expression was associated with improved overall 
survival in NSCLC with adjuvant therapy65. Also, in NSCLC patients treated with EGFR 
inhibitors the response rate, time to progression and survival was higher in PD-L1 positive vs 
PD-L1 negative patients, but with no difference in PD1 positive vs PD-1 negative groups47 
However, we failed to obtain this correlation in our data when the prognostic value of the 
markers was analyzed individually. This discrepancy could be explained by methodological 
differences as we performed quantitative PCR whereas Velcheti et al. used IHC and in situ 
hybridization. But the IHC determinations of PD1 and PDL1 at the protein levels in NSCLC 
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is heterogeneous even with interassay discordance. This differences are caused by the 
antibodies used, with a range in specificity and affinity66 and tests that harmonize immune 
checkpoint determinations in NSCLC and other cancers are indeed needed67. For this reason 
we selected for our study the use of RTqPCR, the gold standard method for gene expression 
quantification with high sensitivity and specificity and clinically applicable for detecting 
patient subgroups with specific prognostic characteristics. Other advantages of this 
technology are that it requires a low RNA input, it is less time consuming than other methods, 
and it is robust and flexible. This is of great importance because current clinicopathological 
staging methods have limited success in predicting patient survival and great outcome 
uncertainty for same-stage NSCLC cancers remains and today, we still cannot predict which 
patients will be cured and which ones will suffer recurrence or death after surgical resection. 
Very recently, an in silico study using mRNA data from The Cancer Genome Atlas (TCGA) 
from 11 tumor types has demonstrated heterogeneous immune infiltrates are present and in 
general are linked to improved prognosis68. If these predictive markers are a reflection of a 
pre-existing immune recognition, and taking the theory that predictive markers are also likely 
to be of prognostic value into account69, our results suggest that immune checkpoint marker 
expression may also be of future value as a new prognostic NSCLC biomarker. Thus, the 
immune checkpoint score may reflect a favorable immune context, in which the immune 
system recognizes the tumor. We propose that these results may also have some therapeutic 
value for managing NSCLC via emerging targeted immunotherapies, especially immune 
checkpoint blockade-based therapies, and so further studies to asses both of these uses should 
be conducted in order to better understand these processes.  
Taken together, our results indicate the existence of two possible immune-scenarios in 
NSCLCs. In the first, the tumor is recognized by the immune system and a T-cell response is 
activated, which in turn activates also immunoregulatory pathways. In this case patients had 
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better outcomes. In the second scenario, which is associated with worse outcomes, the 
immune system does not recognize the tumor and there is no immune response activation, 
therefore immunoregulatory pathway activation is not required. These results provide new 
insight into the tumor immunity field in NSCLC, and could be useful in the future 
development of prognostic and therapeutic tools. 
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Patients and Methods 
Patients and tissue samples 
This retrospective study included 178 patients with resected NSCLC from the General 
University Hospital of Valencia who underwent surgery between 2004 and 2013 and who fit 
the eligibility criteria: resected, non-pretreated stage I to IIIA patients (according to the 
American Joint Committee on Cancer Staging manual) with a histological diagnosis of 
NSCLC. The study was conducted in accordance with the Declaration of Helsinki, and the 
institutional ethical review board approved the protocol. The most relevant demographic and 
clinicopathological characteristics of the cohort are shown in Table 1. Patient tumor and 
adjacent normal lung specimens were obtained at the time of surgery and were preserved in 
RNAlater (Applied Biosystems, USA) to avoid degradation of RNA. The samples were 
frozen at -80° C until the analysis. REMARK recommendations on the studies of prognostic 
tumor markers found in tissues, blood and other body fluids were followed70. Relapse-free 
survival (RFS) was estimated as the time from surgery to recurrence or death from the 
disease, whereas overall survival (OS) was defined as the time from diagnosis to the date of 
death or last follow up. Additionally, K-RAS mutation status was assessed for the whole 
cohort using the theraScreen® KRAS Pyro® kit (Qiagen). This kit is used for quantitative 
detection of mutations in codons 12, 13, and 61 of the human KRAS gene by pyrosequencing. 
Quantitative real time PCR of immune-related genes 
RNA from frozen tissue samples was extracted using standard TRIZOL (Invitrogen) methods. 
RNA was reverse-transcribed using the High Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems, USA) following the manufacturer’s instructions with 1.0 µg of total 
RNA using random hexanucleotides. The thermal cycling conditions were as follows: 10 min 
at 25° C, 120 min at 37° C and 5 s at 85 °C. RTqPCR was performed using Universal Master 
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Mix and TaqMan Gene Expression Assay (Applied Biosystems, USA), to analyze the relative 
expression of 20 immune-related genes: Chemokine ligand 2 (CCL2; assay ID 
Hs00234140_m1), CCL22 (Hs99999075_m1), CD1C (Hs00233509_m1), CD127 
(Hs00233682_m1), CD209 (Hs00253550_m1), CD25 (Hs00166229_m1), CD4 
(Hs00181217_m1), CD8 (Hs00233520_m1), C-type lectin domain family 4, member C 
(CLEC4; Hs01092462_m1), cytotoxic T-lymphocyte-associated protein 4 (CTLA4; 
Hs01011591), forkhead box P3 (FOXP3; Hs00203958_m1); indolamine-1 (IDO1; 
Hs00984148_m1) interleukin 10 (IL10; Hs00961622_m1), IL23A (Hs00413259_m1), lectin 
galactoside-binding soluble 1 (LGALS1; Hs00355202_m1), LGALS2 (Hs00197810_m1), 
neuropilin 1 (NRP1; Hs00826125_m1), programmed cell death 1 (PD1; Hs01550088_m1), 
PDL1 (Hs01125301_m1), and transforming growth factor beta 1 (TGFB1; Hs00171257_m1). 
Using GeNorm software, actin beta (ACTB; Hs01060665_g1), glucuronidase beta (GUSB; 
Hs01558067_m1), and cyclin-dependent kinase inhibitor (CDKN1B; Hs00153277_m1) were 
use as endogenous controls.  The thermal cycling parameters were as follows: 2 min at 50 °C 
and 10 min at 95 °C, followed by 40 cycles of 15 s at 95 °C and 1 min at 60 °C. For efficiency 
calculations of each gene, we used the random-primed qPCR Human Reference cDNA 
(Clontech, USA). Relative gene expression levels were expressed as the ratio of target gene 
expression to reference gene (GUSB) expression by using the Pfaffl formula71. It was 
considered a gene to be overexpressed when the median of the relative gene expression of the 
pathological area referred to the adjacent healthy tissue was higher than 2 and underexpressed 
when it was less than 0.5. Gene expression levels were dichotomized as “high” and “low” 
according to the median of each case. 
Statistical analysis 
 17
Non-supervised hierarchical analysis was carried out with Cluster software (version 3.0) and 
visualized with Tree View software version 1.0.6 which can be found at 
http://rana.lbl.gov/EisenSoftware.htm 72. All analyses were carried out on normalized and 
log2-transformed dataset values. Uncentered correlation was used as the similarity metric and 
average linkage was used as the clustering method. Continuous variables were compared by 
non-parametric Mann–Whitney U and Kruskall-Wallis tests. A Spearman rank test was used 
to test for correlations between continuous variables, and the association between 
dichotomized variables was evaluated by the Chi-square test. Survival analysis was performed 
using a univariate Kaplan-Meier (log-rank) test method with clinicopathological variables, 
dichotomized gene expression marker levels, and immune cell infiltration levels. Finally, to 
assess the independent value of the tested biomarkers, a Cox proportional hazard model for 
multivariate analyses was used. All significant variables from the univariate analyses were 
entered into the multivariate analyses in a forward stepwise Cox regression analysis. 
Furthermore, we also calculated gene expression scores based on multi-gene signatures using 
a method previously reported25,26. Univariate Cox regression analysis on the training cohort 
was used to select genes associated with mortality (Z-score > 2) which were afterwards 
included in a multivariate risk model. All genes were included for these purposes, and 
expression values for all analyses are continuous variables. For multivariate Cox regression 
models, missing values for genes were replaced with the average value. A probability of 95% 
(p < 0.05) was considered statistically significant for all analyses. The statistical analyses 
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Table 1. Clinicopathological characteristics of the patients included in the study. 
Characteristics N % 
Age at surgery (median, 
range): 
65 [26-85] 
Gender   
Male 154 86.5 
Female 24 13.5 
Stage   
I 105 59 
II 35 19.7 
IIIA 38 21.3 
Histology   
SCC 84 47.2 
ADC 74 41.6 
Others 20 11.2 
Performance Status   
0 118 66.3 
1-2 60 33.7 
Differentiation grade   
Poor 43 24.2 
Moderate 77 43.3 
Well 31 17.4 
NS 27 15.2 
Smoking Status   
Current 86 48.3 
Former 72 40.4 
Never 20 11.3 
ADC, adenocarcinoma; SCC, squamous cell carcinoma; NS, not specified. 
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Table 2. Results from the multivariate Cox regression model for OS. 
Variable Regression Coefficient SE p-value HR 95% CI 
PD1 expression -0.116 0.075 0.121 0.890 0.769-1.031 
CTLA4 expression -0.058 0.035 0.102 0.944 0.881-1.012 
CI, confidence interval; HR, hazard ratio; OS, overall survival; SE, standard error. 
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Table 3. Multivariate Cox regression model results, including all the significant variables. 
  OS  RFS  
Variables HR 95% CI p-value HR 95% CI p-value
KRAS status 




























CI, confidence interval; HR, hazard ratio; OS, overall survival; RFS, relapse-free survival; 
WT, wild type. 
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Legend to the figures 
Figure 1. Hierarchical cluster based on selected gene expression. Patients in the original 
cohort were clustered into a hierarchical tree based on the expression of immune related 
genes. The clustering separated the patients into two distinct groups. Red indicates high 
expression and green indicates low expression levels. 
 
Figure 2. Kaplan-Meier plots for OS and RFS according to the clustering classification of 
patients. a) RFS and b) OS. Solid line represents patients classified in Cluster I, whilst dashed 
line represents patients in Cluster II. P-values were calculated using the Kaplan-Meier test. 
 
Figure 3. Kaplan-Meier plots for OS and RFS according to the immune checkpoint 
expression score (ICS). The score was divided as low and high according to its median. Solid 
line represents patients with low levels of expression, whilst dashed line represents patients 





Supplementary Figure 1. Kaplan-Meier plots for OS and RFS according to gene expression 
levels. a-b) IL23A, and c-d) LGALS2. Gene expression levels were dichotomized according 
to the median. Blue line represents patients with low levels of expression, whilst green line 





Supplementary Figure 2. Kaplan-Meier plots for OS and RFS according to gene expression 
levels in ADCs. a-b) CTLA4; and c-d) IL10. Gene expression levels were dichotomized 
according to the median. Blue line represents patients with low levels of expression, whilst 







Supplementary Figure 3. Univariate analysis of the expression of 20 immunoregulatory 
genes for OS. The genes are ranked based on their predictive power (univariate Z-score). 
Dashed lines indicate |Z-score|= 1.5. This criterion was used to select genes to include in the 
multivariate Cox regression model used to calculate the expression score 
 
 
